Targeted therapy combined with immunotherapy <i>vs</i> trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer.

However, this difference in PFS did not reach statistical significance (HR = 1.4322, 95%CI: 0.9406- 2.181, P = 0.092) (Figure 2 ).

also in 111,027 other papers

Notably, its incidence is rising annually, with an increasing trend toward younger onset, posing significant threats to global health[ 1 ].

also in 63,971 other papers